Summary
The aim of this study was to investigate the possible therapeutic effect of 13-cis-retinoic acid plus interferon alpha-2a in patients with inoperable squamous cancer of the esophagus. Patients with advanced, measurable, histologically confirmed squamous carcinoma of the esophagus with an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 who had adequate bone marrow, liver, and renal function were eligible for study. Patients were given cis-retinoic acid 1 mg/kg/day per mouth continuously and interferon alpha-2a 3 Mu/day for 3 days followed by 6 Mu subcutaneously daily thereafter. Seventeen patients were entered on study. Fifteen patients were evaluable for toxicity. The most common toxicities were grade 1 and 2 cheilitis, dry skin and flu-like symptoms which occurred in all patients. Two patients had grade 3 toxicity (1 anorexia and 1 fatigue). No grade 4 toxicity occurred. Fifteen patients were evaluable for response. No objective response was documented. The median survival time was 15 weeks. With no response seen it is unlikely that the combination of treatment as used in this study will be of benefit in patients with advanced squamous cancer of the esophagus.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Sitas F, Terblanche M, Madhoo J: National Cancer Registry of South Africa, 1996
Mannel A, Murry W: Oesophageal cancer in South Africa. A review of 1926 cases. Cancer 64:2604–2608, 1989
Ezdinli EZ, Gelber R, Desai DV, Falkson G, Moertel CG, Hahn RG: Chemotherapy of advanced esophageal carcinoma: Eastern Cooperative Oncology Group experience. Cancer 46:2149–2153, 1980
Falkson G: Methyl-GAG (NSC 32946) in the treatment of oesophagus cancer. Cancer Chemother Rep 55:209–212, 1971
Davis S, Shanmugathasa M, Kessler W: cis-Dichlorodiammineplatinum (II) in the treatment of esophageal carcinoma. Cancer Treat Rep 64:709–711, 1980
Ansell SM, Alberts AS, Falkson G: Ifosfamide in advanced carcinoma of the esophagus: a phase II trial with severe toxicity. Am J Clin Oncol 12:205–207, 1989
Alberts AS, Falkson G, Badat M, Terblanche APS, Schmid EU: Trimetrexate in advanced carcinoma of the esophagus. Invest New Drugs 6:319–321, 1986
Falkson G, Ryan LM, Haller DG: Phase II trial for the evaluation of trimetrexate in patients with inoperable squamous carcinoma of the esophagus. Am J Clin Oncol 15:433–435, 1992
Engstrom PF, Lavin PT, Klaassen DJ: Phase II evaluation of mitomycin and cisplatin in advanced esophageal carcinoma. Cancer Treat Rep 67:713–715, 1983
Kolaric K, Maricic Z, Dujmovic I, Roth A: Therapy of advanced esophageal cancer with bleomycin, irradiation and combination of bleomycin with irradiation. Tumori 62:255–262, 1976
Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG: Therapy for gastrointestinal cancer with nitrosoureas alone and in drug combination. Cancer Treat Rep 60:729–732, 1976
Kelsen DP, Bains M, Cvitkovic E, Golby R: Vindesine in the treatment of esophageal carcinoma: a phase II study. Cancer Treat Rep 63:2019–2021, 1979
Coonley CJ, Bains M, Heelan M, Dukeman M, Kelsen DP: Phase II study of etoposide in the treatment of esophageal carcinoma. Cancer Treat Rep 67:397–398, 1983
Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L, Emami B: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326:1593–1598, 1992
Alberts AS, Burger W, Greef F, Schoeman L, Friediger D, Nel J, Steyn E, Schmid EU, Falkson G: Severe complications of 5-fluorouracil and cisplatin with concomitant radiotherapy in inoperable non-metastatic squamous cell oesophageal cancer after intubation-early termination of a prospective randomised trial. EurJ Cancer 28A:1005–1006, 1992
Lippman SM, Parkinson DR, Itri LM, Weber RS, Schantz SP, Ota DM, Schusterman MA, Krakoff IW, Gutterman JU, Hong WK: 13-cis-retinoic acid and interferon alfa-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 84:235–241, 1992
Lippman SM, Kavanagh JJ, Paredes-Espinoza M, Delgadillo-Madrueno F, Paredes-Cassilas P, Hong WK, Holdener E Krakoff IH: 13-cis-retinoic acid plus interferon alfa-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 84:241–245, 1992
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655, 1982
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Slabber, C.F., Falkson, G., Burger, W. et al. 13-Cis-retinoic acid and interferon alpha-2a in patients with advanced esophageal cancer: A phase II trial. Invest New Drugs 14, 391–394 (1996). https://doi.org/10.1007/BF00180816
Issue Date:
DOI: https://doi.org/10.1007/BF00180816